{"id":"W4293109639","doi":"10.1038/s41467-022-32591-8","title":"The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Université Laval; Juravinski Cancer Centre; University of British Columbia; CancerCare Manitoba; Nova Scotia Cancer Centre; University of Ottawa; Dalhousie University; Bausch Health (Canada); Ottawa Hospital; Moncton Hospital; Centre Hospitalier de l’Université de Montréal; University of Toronto; Université de Sherbrooke; Université de Montréal; Cancer Care Ontario; Pancreas Centre (Canada); McGill University; BC Cancer Agency; Vancouver General Hospital; University of Calgary; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Jewish General Hospital","funders":"Terry Fox Research Institute","keywords":"Gemcitabine; Durvalumab; Nab-paclitaxel; Tremelimumab; Medicine; Pancreatic ductal adenocarcinoma; Oncology; Paclitaxel; Internal medicine; Adenocarcinoma; Cancer research; Pancreatic cancer; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001092886,0.0001736169,0.0006222498,0.0001832599,0.0008737622,0.00002008786,0.000416399,0.0000954079,0.00008623413],"category_scores_gemma":[0.0007150228,0.0001039202,0.00004696378,0.0004854329,0.0008180845,0.00007234885,0.000407872,0.00126079,7.732675e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008989454,"about_ca_system_score_gemma":0.0007003372,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002497216,"about_ca_topic_score_gemma":0.0006755044,"domain_scores_codex":[0.9978132,0.000813505,0.0004362596,0.0002351005,0.0004436543,0.0002582809],"domain_scores_gemma":[0.9967682,0.001645018,0.0001773881,0.001142646,0.0001552314,0.0001114839],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5006226,0.01645232,0.403013,0.0002444729,0.003027272,0.0003283885,0.02448056,0.000002337626,0.002176342,0.0154354,0.001362615,0.03285461],"study_design_scores_gemma":[0.6131995,0.09848703,0.2364846,0.0002699862,0.002150288,0.003212295,0.02377507,0.006309743,0.0001521901,0.002348117,0.01289257,0.0007185977],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9703747,0.01967798,0.000004409033,0.006981464,0.00003807529,0.001884861,0.00004471026,0.00001893198,0.0009748778],"genre_scores_gemma":[0.9913267,0.005362853,0.001793525,0.0002339723,0.00003578885,0.0006378323,0.00006934946,0.00002444658,0.000515532],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1665284,"threshold_uncertainty_score":0.6720361,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06866649903967512,"score_gpt":0.4222206252968865,"score_spread":0.3535541262572114,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}